Cambridge’s reputation as a world-class hub for life sciences suffered a setback on Friday after AstraZeneca paused a £200m expansion at its Discovery Centre. The project, first announced in March 2024, promised to create 1,000 jobs and strengthen Britain’s pharmaceutical industry.
The decision is the second major retreat from the UK by the firm this year, following its withdrawal from a planned £450m vaccine facility in Liverpool. It also mirrors moves by rivals such as Merck, which recently abandoned a £1bn research site in London.
An AstraZeneca spokesperson confirmed: “We constantly reassess the investment needs of our company and can confirm our expansion in Cambridge is paused.”
Industry leaders warn the shift reflects broader pressures. Over the past decade, UK spending on medicines has declined from 15% of the NHS budget to just 9%. In contrast, other developed nations invest between 14% and 20%. Many global pharmaceutical firms are now turning to the United States, where President Donald Trump has pushed aggressively for domestic investment and threatened tariffs on imports.
In July, AstraZeneca chief executive Pascal Soriot unveiled a $50bn (£36.9bn) US investment plan for research and manufacturing. Days later, Merck revealed it would abandon its nearly complete King’s Cross site, shifting operations to the US and cutting British jobs.
The shelved Cambridge project would have expanded AstraZeneca’s existing Discovery Centre, already home to 2,300 scientists. Its suspension leaves none of the £650m in life sciences investments announced by the previous UK government currently moving forward.
Successive governments have hailed pharmaceuticals as a cornerstone of Britain’s economy. Former chancellor Jeremy Hunt called the sector “crucial for the country’s health, wealth and resilience”, while his successor Rachel Reeves praised AstraZeneca as one of the nation’s “great companies” only days before the Liverpool project was scrapped.
Analysts warn that without a stronger partnership between government and industry, the UK risks losing its position as a global leader in research and development. For Cambridge, a city that has long been at the heart of scientific innovation, the pause signals a sobering reminder of how international competition and domestic policy collide.
